ORCHIDPHAR

Orchid Pharma Limited has informed the Exchange that the trading in Equity Shares of Orchid Pharma Limited shall be suspended w.e.f. July 25, 2019 (i.e. closing hours of trading on July 24, 2019) on account of Reduction of Share Capital.

ORCHIDPHAR: The Exchange had sought clarification from Orchid Pharma Limited with respect to announcement dated 01-Mar-2019, regarding 'Disclosure under Regulation 30 of the SEBI (LODR) Regulations,2015'.".On basis of above the Company is required to clarify following:1. Any other material information not involving commercial secrets2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified3. Approval of resolution plan by the Tribunal or rejection, if applicable4. Filing of resolution plan with the Tribunal5. Number

ORCHIDPHAR:The Exchange has sought clarification from Orchid Pharma Limited with respect to announcement dated 01-Mar-2019, regarding " Orchid Pharma Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (LODR) Regulations,2015'.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets<br> 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified<br> 3. Approval of resolution plan by the Tribunal or rejecti

The Exchange has sought clarification from Orchid Pharma Limited with respect to recent news item captioned "Aurobindo, DRL lead race to buy orchid". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Orchid Pharma Limited has submitted their response.

The Exchange has sought clarification from Orchid Pharma Limited with respect to recent news item captioned "Aurobindo, DRL lead race to buy orchid". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

News about Orchid Chemicals & Pharmaceuticals Limited.The media had reports that "Orchid Pharmaceuticals in talks with banks to rejig debt".The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Orchid Chemicals & Pharmaceuticals Limited has vide its letter inter-alia stated, "The company is currently in talks with banks to explore the possibility of converting its rupee debt into dollar denominated debt. This plan is to try and reduce the

The Exchange has sought clarification from Orchid Chemicals & Pharmaceuticals Ltd., with respect to recent news item captioned "Orchid Pharmaceuticals in talks with banks to rejig debt". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Spurt in Volume : Substantial increase in trading volumes have been observed in Orchid Chemicals & Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Orchid Chemicals & Pharmaceuticals Limited has vide its letter inter-alia stated,"We confirm that there are no material developments and plans other than those already communicated to the exchanges in line with the listing agreement. The company is unaware of the

News Verification : The media had reports on September 18, 2010 that the promoters of Orchid Chemicals & Pharmaceuticals Limited may buy 13.02% stake from Ranbaxy Laboratories Ltd. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Orchid Chemicals & Pharmaceuticals Limited has vide its letter inter-alia stated," The current holding of Solrex Pharmaceuticals in Orchid is around 7.92%. We do not have any information wi

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange with reference to a news item appearing in a website attributing to the Company an announcement that the Company (Orchid) has received US FDA approval for its generic product Imipenem-Cilastatin 250 mg Injection. The Company has clarified that Orchid had made no such announcement and states that its ANDAs for the said injection in applicable dosage forms and strengths are under review by the US FDA.

Clarification of News : The press had reports on Jan 01, 2005 that Orchid Chemicals Limited is likely to sell one of its molecules. Further, the company might also launch a new molecule. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Orchid Chemicals Limited has vide its letter inter-alia stated, "The news item was completely based on market rumours".